Until recently, there had not been a new product introduced in the wound care arena that had gone through the Food and Drug Administration (FDA) approval process in several years. The FDA recently announced the approval of the Omnigraft Dermal Regeneration Matrix (Integra LifeSciences) for its new indication in the treatment of diabetic foot ulcers in the outpatient clinical setting.
The treatment of diabetic neuropathy includes management of symptoms such as paresthesia and dysesthesia as well as efforts to interdict the progression of neuropathy. Although there is much discussion regarding the positive symptoms of neuropathy, such as pain or burning, it is the negative symptoms that are frequently responsible for deformity, ulceration and limb loss.
David G. Armstrong DPM MD PhD | 3,551 reads | 0 comments | 01/01/2016
When we tackle the problem of diabetic foot ulcers, the idea is not just the mortality. The idea is that diabetes is like cancer but we do not tend to treat diabetes like cancer and we should be. We should be communicating and using the same language in terms of morbidity and mortality as we do with cancer. When we look at the data from a new study, the mortality rate is similar to the rate of very aggressive cancer.1
Michael I. Gazes, DPM, MPH, Amber R. Morra, DPM, and Peter A. Blume, DPM, FACFAS | 5,326 reads | 0 comments | 04/21/2016
Collagen-based products reportedly promote increased fibroblast proliferation and inhibit excessive matrix metalloproteinases in addition to other benefits for diabetic foot ulcerations. With this in mind, these authors take a closer look at the research on collagen modalities, comparing various established and emerging options.
Wayne J. Caputo, DPM, FACFAS, and George J. Fahoury, DPM, FACFAS | 3,494 reads | 0 comments | 02/22/2016
The goal of wound management is to attain cost effective wound closure to reestablish function.1 This is especially true with lower extremity wounds that are debilitating and often lead to a temporary or permanent disability.
At one point, limb loss due to diabetes occurred every 30 seconds. Recent research has reduced the figure to every 20 seconds.1-3 Eighty-five percent of lower limb amputations follow incidence of a diabetic foot ulcer and most are preventable.4,5
Chronic wounds, typically defined as wounds that have not decreased in size by 50 percent after four to six weeks of treatment, are often accompanied by complications including peripheral neuropathy, diabetes, peripheral vascular disease (PVD) and poor patient adherence.1-4